Together with data in Table 1, these data suggest that polymorphic CASR variants at the rs1801725 SNP contribute to the development of breast cancer-induced hypercalcemia and consequently, the high circulating calcium associated progression of BC into larger or aggressive breast tumors [3–5] in the up to 20% of women with mutations at the rs1801725 SNP. Here, CASR is linked to hypercalcemia disease.